Immunocore Holdings plc Files 8-K with Corporate Updates

TL;DR

Immunocore filed an 8-K on Dec 31, 2024, reporting director/officer changes and financial statements.

AI Summary

Immunocore Holdings plc filed an 8-K on January 2, 2025, reporting events as of December 31, 2024. The filing indicates changes in directors or officers, potential new compensatory arrangements, and includes financial statements and exhibits. Specific details regarding the nature of these changes or financial performance are not elaborated in this header information.

Why It Matters

This filing signals potential changes in the company's leadership or compensation structures, which could impact investor confidence and future strategic direction.

Risk Assessment

Risk Level: low — The filing is a standard corporate disclosure and does not, on its own, indicate significant financial distress or operational risk.

Key Players & Entities

• Immunocore Holdings plc (company) — Registrant
• December 31, 2024 (date) — Date of earliest event reported
• January 2, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $500,000 — eceive an initial annual base salary of $500,000 per year and be eligible to receive an
• $200,000 — ll also receive a cash sign-on bonus of $200,000, payable in three installments as follo
• $100,000 — yable in three installments as follows: $100,000 payable on January 31, 2025, and $50,00
• $50,000 — 00,000 payable on January 31, 2025, and $50,000 payable on each of January 30, 2026 and

Filing Documents

• ef20040795_8k.htm (8-K) — 40KB
• ef20040795_ex99-1.htm (EX-99.1) — 17KB
• image00004.jpg (GRAPHIC) — 3KB
• image00005.jpg (GRAPHIC) — 7KB
• 0001140361-25-000008.txt ( ) — 216KB
• imcr-20241231.xsd (EX-101.SCH) — 4KB
• imcr-20241231_lab.xml (EX-101.LAB) — 21KB
• imcr-20241231_pre.xml (EX-101.PRE) — 16KB
• ef20040795_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Chief Financial Officer On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc ("Parent" and, together with Immunocore LLC, the "Company"), entered into an employment agreement (the "Employment Agreement") with Travis Coy, pursuant to which Mr. Coy will serve as the Company's Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company's principal financial officer, effective as of January 1, 2025 (the "Effective Date"). In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company's board of directors (the "Board"), effective as of the Effective Date. Mr. Coy, age 44, previously served as Vice President, Head of Transactions and M&A, Corporate Business Development at Eli Lilly and Company ("Lilly"), a position he held since October 2019. Prior to this role, Mr. Coy held a variety of finance and business development experiences of increasing responsibility at Lilly since he joined in 2003, including positions as Vice President, Transactions - Oncology and Diagnostics; Vice President, Transactions - Cardiometabolic Diseases, Drug Delivery and Devices; Finance Director of the Oncology Business Unit; Director of Investor Relations; Director of Corporate Finance and Investment Banking; and other financial controllership roles. Before transitioning to finance and business development, he served as a chemist in Lilly's research laboratories and as a production manager for Milliken & Company. Mr. Coy holds an M.B.A. from the Ross School of Business at the University of Michigan and a B.S. in Chemistry from Rose-Hulman Institute of Technology. Pursuant to the Employment Agreement, Mr. Coy will receive an initial annual base salary of $500,000 per year and be eligible to r

01

Item 7.01. Regulation FD Disclosure On January 2, 2025, the Company issued a press release announcing the appointment of Mr. Coy as the Company's Executive Vice President, Chief Financial Officer and Head of Corporate Development, a copy of which is attached hereto as Exhibit 99.1 and is hereby incorporated by reference. The information contained in to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated January 2, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: January 2, 2025 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR